Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19372896 | 0.84 | PDPK1 (0.38) | P2RX3P2RX2CDK1CCNB1CDK2 | |
| SCHEMBL17175013 | 0.81 | DHFR (0.33) | PNP | |
| SCHEMBL17175024 | 0.79 | PARP14 (0.31) | — | |
| SCHEMBL17175016 | 0.79 | CCNA2 (0.37) | P2RX3P2RX2CDK1CCNB1CCNA2 | |
| SCHEMBL17175022 | 0.71 | MTAP (0.35) | — | |
| SCHEMBL19372892 | 0.71 | DHFR (0.35) | PNP | |
| SCHEMBL17175012 | 0.70 | MAPKAPK2 (0.43) | P2RX3P2RX2ALDH1A1 | |
| SCHEMBL22907452 | 0.70 | PNP (0.56) | PNP | |
| SCHEMBL2611029 | 0.67 | P2RX3 (0.45) | P2RX3P2RX2 | |
| SCHEMBL20028299 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | MIDCAP FINANCIAL TRUST, AS AGENT | 2017-09-21 | — | — | US | disclosed |
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BIOCRYST PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | PNP 17/4885P2RX3 2843/4885P2RX2 2840/4885 |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | PNP 17/4885P2RX3 2843/4885P2RX2 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.